Donepezil, a cholinesterase inhibitor used for the treatment of Alzheimer's disease, increased serum BDNF in Alzheimer's disease patients [19], while atorvastatin, a HMG-CoA reductase inhibitor, increased serum BDNF levels and improved functional recovery following stroke [20]. Here, HMGCR is linked to early-onset autosomal dominant Alzheimer disease.